Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics
International Journal of Drug Discovery and Pharmacology · 2023
DOI: 10.53941/ijddp.0201002 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Discovery and Pharmacology, 2023. Verfasst von Guo Hu und 1 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Duchenne muscular dystrophy is caused by inadequate generation of functional dystrophin protein. Traditional clinical treatments can only slightly mitigate the progression of the disease, but not completely stem or reverse the decline in muscle function. Therapies aimed at dystrophin recovery are currently under development, among which are exon skipping and stop codon readthrough therapies. They are now used in clinics, while gene addition therapies are in phase III clinical trials. Gene editing therapies have also been approved for the first clinical trial recently. This review will discuss these emerging therapies, clinical trials, and directions for future developments.
Zitieren
APA
Hu, G., & Chen, C. (2023). Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics. International Journal of Drug Discovery and Pharmacology. https://doi.org/10.53941/ijddp.0201002
Vancouver
Hu G, Chen C. Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics. International Journal of Drug Discovery and Pharmacology. 2023. doi:10.53941/ijddp.0201002
BibTeX
@article{Hu2023,
author = {Hu, Guo and Chen, Chen},
title = {Promising Treatments for Duchenne Muscular Dystrophy: Restoring Dystrophin Protein Expression Using Nucleic Acid Therapeutics},
journal = {International Journal of Drug Discovery and Pharmacology},
year = {2023},
doi = {10.53941/ijddp.0201002}
}
EUVIMED